Ephrin Receptor

Ephrin Receptor Related Products (23):

By Effects:	Inhibitors (12) Agonists (4) Antagonists (5)

Cat. No.	Product Name	Effect	Purity

HY-13258A

NVP-BHG712	Inhibitor	99.70%
NVP-BHG712 is an oral active EphB4 kinase autophosphorylation inhibitor, with IC₅₀ values of 3.3 nM and 3.0 nM for EphA2 and EphB4, respectively.

HY-18007

ALW-II-41-27	Inhibitor	99.63%
ALW-II-41-27 is a Eph family tyrosine kinase inhibitor with an IC₅₀ of 11 nM for Eph2.

HY-18833

ALW-II-49-7	Inhibitor	99.80%
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC₅₀ value of 40 nM in cell.

HY-133178

Urolithin D	Antagonist	99.72%
Urolithin D is competitive and reversible antagonist of EphA receptors. Urolithin D exhibits intra-classes selectivity.

HY-P0177

123C4	Agonist	99.71%
123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4, with a K_i value of 0.65 μM.

HY-P10579

123B9	Agonist
123B9, a tumor-homing agent, is a potent and selective EphA2 agonist with a K_d value of 4.0 μM. 123B9 selectively targets the EphA2 tyrosine kinase receptor ligand-binding domain. 123B9 does not appreciably inhibit the ligand binding domains of the most closely related EphA3 and EphA4 receptors.

HY-P10412

A11	Inhibitor
A11 (ANXA1-derived 11 amino acid–long peptide) is an ANXA1-EphA2 interaction blocker peptide. A11 decreases ANXA1 bound to EphA2 and increased Cbl (an E3 ubiquitin ligase of EphA2) bound to EphA2. A11 efficiently decreases EphA2 level, and substantially increases EphA2 ubiquitination. A11 increases EphA2 internalization and colocalization of EphA2 and Cbl in the NPC cells. A11 inhibits nasopharyngeal carcinoma (NPC) cell proliferation, migration and invasion. A11 inhibits angiogenesis.

HY-136358

LDN-211904	Inhibitor
LDN-211904 is an inhibitor of EphB3 receptor tyrosine kinase. LDN-211904 enhances the inhibitory activity of EphB3 kinase by maintaining the 2-chloroaniline group and introducing a phenyl or small electron donor substituent to the 5 position of pyrazole and [1,5-a] pyridine. LDN-211904 can be used as a molecular probe to study the function and signaling pathways of EphB3 receptors, especially in the nervous system during neurodevelopment and adulthood.

HY-13258

NVP-BHG712 isomer		99.58%
NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4.

HY-107460

LDN-211904 oxalate	Inhibitor	≥99.0%
LDN-211904 oxalate (compound 32) is a potent and selective EphB3 inhibitor with an IC₅₀ of 0.079 µM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with cetuximab could be effective in inhibiting STAT3-activated CSC stemness and cetuximab resistance in CRC.

HY-123607

UniPR129	Antagonist	99.23%
UniPR129 is a potent Eph/ephrin antagonist with IC₅₀s of 0.84-3.01 μM. UniPR129 has the potential for the research of cancer disease.

HY-P99655

Ifabotuzumab	Inhibitor
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K_D=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10⁺ cells and improves pulmonary fibrosis.

HY-147637

EphA2 agonist 1	Agonist	99.32%
EphA2 agonist 1 (Compound 7bg) is a potent EphA2 receptor agonist. EphA2 agonist 1 shows great potency and selectivity toward EphA2 overexpressed glioblastoma cells and stimulates EphA2 phosphorylation.

HY-114199

Eph inhibitor 1	Inhibitor	98.04%
Eph inhibitor 1 is a potent Eph inhibitor. Eph inhibitor 1 has the potential for the research of neurological disorders.

HY-P2264

KYL peptide	Inhibitor	99.09%
KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC₅₀:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses.

HY-P3717

Targefrin		99.45%
Targefrin is a potent EphA2-targeting agent, acts as an antagonist. Targefrin binds EphA2-LBD with 21 nM dissociation constant and an IC₅₀ value of 10.8 nM. Targefrin induces cellular receptor internalization and degradation in several pancreatic cancer cell lines.

HY-157019

UniPR1447	Antagonist
UniPR1447 is Dual EphA2 and EphB2 antagonist, with an IC₅₀ of 6.6 μM for EphA2−ephrin-A1 binding.

HY-161171

Antimalarial agent 37	Inhibitor
Antimalarial agent 37 (compound 33) is a selective inhibitor against Type Ⅱ kinase with antiplasmodial activity. Antimalarial agent 37 exhibited cytotoxicity and selectivity towards cancer cells HepG2 and MCF 7.

HY-146375

UniPR505	Antagonist
UniPR505 (Compound 14) is an EphA2 antagonist with an IC₅₀ of 0.95 µM. UniPR505 displays anti-angiogenic properties.

HY-131005

Eph inhibitor 2	Inhibitor
Eph inhibitor 2 (Example 35) is a Eph family tyrosine kinase inhibitor.

Name
Email *

	Sorry, but the email address you supplied was invalid.